CoChat

Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Many DNA tumor viruses promote cellular transformation by inactivating the critically important tumor suppressor protein p53. In contrast, it is not known whether p53 function is disrupted by hepatitis C virus (HCV), a unique, oncogenic RNA virus that is the leading infectious cause of liver cancer in many regions of the world. Here we show that HCV-permissive, liver-derived HepG2 cells engineered to constitutively express microRNA-122 (HepG2/miR-122 cells) have normal p53-mediated responses to DNA damage and that HCV replication in these cells potently suppresses p53 responses to etoposide, an inducer of DNA damage, or nutlin-3, an inhibitor of p53 degradation pathways. Upregulation of p53-dependent targets is consequently repressed within HCV-infected cells, with potential consequences for cell survival. Despite this, p53 function is not disrupted by overexpression of the complete HCV polyprotein, suggesting that altered p53 function may result from the host response to viral RNA replication intermediates. Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9-mediated ablation of double-stranded RNA (dsRNA)-activated protein kinase R (PKR) restored p53 responses while boosting HCV replication, showing that p53 inhibition results directly from viral activation of PKR. The hepatocellular abundance of phosphorylated PKR is elevated in HCV-infected chimpanzees, suggesting that PKR activation and consequent p53 inhibition accompany HCV infection in vivo . These findings reveal a feature of the host response to HCV infection that may contribute to hepatocellular carcinogenesis. IMPORTANCE Chronic infection with hepatitis C virus (HCV) is the leading cause of liver cancer in most developed nations. However, the mechanisms whereby HCV infection promotes carcinogenesis remain unclear. Here, we demonstrate that HCV infection inhibits the activation of p53 following DNA damage. Contrary to previous reports, HCV protein expression is insufficient to inhibit p53. Rather, p53 inhibition is mediated by cellular protein kinase R (PKR), which is activated by HCV RNA replication and subsequently suppresses global protein synthesis. These results redefine our understanding of how HCV infection influences p53 function. We speculate that persistent disruption of p53-mediated DNA damage responses may contribute to hepatocellular carcinogenesis in chronically infected individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.00121-17

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Comparison of p53 responses in HepG2 and Huh7 cells. (A) Schematic representation of p53, including key functional domains. HepG2 cells express functional, wild-type p53, whereas Huh7 cells express Y220C-mutated p53 that is aberrantly stable and transcriptionally inactive (12, 13). (B) Immunoblots of p53 and its transcriptional targets, p21 and PUMA, in lysates of HepG2 and Huh7 cells treated with increasing concentrations of etoposide (ETOP) or DMSO control for 6 h. β-Actin was used as a loading control.
FIG 1 Comparison of p53 responses in HepG2 and Huh7 cells. (A) Schematic representation of p53, including key functional domains. HepG2 cells express functional, wild-type p53, whereas Huh7 cells express Y220C-mutated p53 that is aberrantly stable and transcriptionally inactive (12, 13). (B) Immunoblots of p53 and its transcriptional targets, p21 and PUMA, in lysates of HepG2 and Huh7 cells treated with increasing concentrations of etoposide (ETOP) or DMSO control for 6 h. β-Actin was used as a loading control.CC BY · PubMed Central
FIG 2 HCV replication inhibits p53 activation following DNA damage. (A) Immunofluorescence confocal microscopy for p53 and HCV core protein in HepG2/miR-122 cells electroporated with genome-length HCV RNA (JFH1-QL) or a nonreplicating control RNA (JFH1/GND) and treated 72 h later with 100 μM etoposide (ETOP) or DMSO for 2 h. Nuclei were labeled with DAPI. Bars, 50 μm. (B) Immunoblots of p53, p21, PUMA, and HCV core protein in HepG2/miR-122 cells electroporated with JFH1-QL or JFH1/GND RNA and treated 72 h later with 50 μM ETOP, 10 μM MDM2 inhibitor (nutlin-3), or DMSO for 6 h. β-Tubulin was used as a loading control. (C) Flow cytometric analysis of p53 and HCV core protein levels in cells treated as described for panel A. Quadrants are based on staining with isotype control antibodies. The frequency of events in each quadrant is represented as the percentage of total gated events. (D) p53 accumulation in cell populations from panel C that do not express HCV core [HCV core (-)] versus cell populations that express HCV core [HCV core (+)]. The numbers indicate the percentages of p53-positive cells following etoposide treatment. (E) Median fluorescence intensity (MFI) values for p53 for the indicated populations are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus standard errors of the means (SEM) (error bars) from three independent experiments. (F) p21 upregulation in HCV core (-) versus HCV core (+) cells treated with 50 μM ETOP or DMSO for 6 h. The numbers indicate the percentages of p21-positive cells following etoposide treatment. (G) MFI values for p21 are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus SEM from three independent experiments. Values that are significantly different (P < 0.0001), by two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple comparisons are indicated by a bar and three asterisks.
FIG 2 HCV replication inhibits p53 activation following DNA damage. (A) Immunofluorescence confocal microscopy for p53 and HCV core protein in HepG2/miR-122 cells electroporated with genome-length HCV RNA (JFH1-QL) or a nonreplicating control RNA (JFH1/GND) and treated 72 h later with 100 μM etoposide (ETOP) or DMSO for 2 h. Nuclei were labeled with DAPI. Bars, 50 μm. (B) Immunoblots of p53, p21, PUMA, and HCV core protein in HepG2/miR-122 cells electroporated with JFH1-QL or JFH1/GND RNA and treated 72 h later with 50 μM ETOP, 10 μM MDM2 inhibitor (nutlin-3), or DMSO for 6 h. β-Tubulin was used as a loading control. (C) Flow cytometric analysis of p53 and HCV core protein levels in cells treated as described for panel A. Quadrants are based on staining with isotype control antibodies. The frequency of events in each quadrant is represented as the percentage of total gated events. (D) p53 accumulation in cell populations from panel C that do not express HCV core [HCV core (-)] versus cell populations that express HCV core [HCV core (+)]. The numbers indicate the percentages of p53-positive cells following etoposide treatment. (E) Median fluorescence intensity (MFI) values for p53 for the indicated populations are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus standard errors of the means (SEM) (error bars) from three independent experiments. (F) p21 upregulation in HCV core (-) versus HCV core (+) cells treated with 50 μM ETOP or DMSO for 6 h. The numbers indicate the percentages of p21-positive cells following etoposide treatment. (G) MFI values for p21 are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus SEM from three independent experiments. Values that are significantly different (P < 0.0001), by two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple comparisons are indicated by a bar and three asterisks.CC BY · PubMed Central
FIG 3 p53 activation is impaired in cells inoculated with infectious HCV. (A) Flow cytometric analysis of HepG2-HFL cells 72 h after mock infection or inoculation with JFH1-QL virus (MOI of 0.5). Cells were gated into mock-infected (-) versus virus-infected (+) populations based on HCV core protein staining in mock-infected cells. The percentage of cells in each population is indicated. (B) p53 accumulation in cells that do not express HCV core [HCV core (-)] versus cells that express HCV core [HCV core (+)]. The cells were treated with 50 μM etoposide or DMSO control for 6 h. Numbers indicate the percentages of p53-positive cells following etoposide treatment. (C) p21 upregulation in HCV core (-) cells versus HCV core (+) cells treated as described for panel B. Numbers indicate the percentages of p21-positive cells following etoposide treatment.
FIG 3 p53 activation is impaired in cells inoculated with infectious HCV. (A) Flow cytometric analysis of HepG2-HFL cells 72 h after mock infection or inoculation with JFH1-QL virus (MOI of 0.5). Cells were gated into mock-infected (-) versus virus-infected (+) populations based on HCV core protein staining in mock-infected cells. The percentage of cells in each population is indicated. (B) p53 accumulation in cells that do not express HCV core [HCV core (-)] versus cells that express HCV core [HCV core (+)]. The cells were treated with 50 μM etoposide or DMSO control for 6 h. Numbers indicate the percentages of p53-positive cells following etoposide treatment. (C) p21 upregulation in HCV core (-) cells versus HCV core (+) cells treated as described for panel B. Numbers indicate the percentages of p21-positive cells following etoposide treatment.CC BY · PubMed Central
FIG 4 HCV inhibition of p53 activation is not mediated by HCV polyprotein expression. (A) Immunoblots of p53, HCV core, and HCV NS5B in UHCV-11 cells maintained in the presence of 1 μg/ml tetracycline (+) or absence of tetracycline (−) and treated with 50 μM etoposide (ETOP) (+) or without ETOP (−) for 6 h. β-Actin was used as a loading control. (B) Flow cytometric analysis of p53 and HCV core protein expression in UHCV-11 cells treated as described for panel A. (C) Flow cytometric analysis of p21 and HCV core protein expression in UHCV-11 cells treated as described for panel A. Quadrants are based on staining with isotype control antibodies. The frequency of events in each quadrant is represented as the percentage of total gated events.
FIG 4 HCV inhibition of p53 activation is not mediated by HCV polyprotein expression. (A) Immunoblots of p53, HCV core, and HCV NS5B in UHCV-11 cells maintained in the presence of 1 μg/ml tetracycline (+) or absence of tetracycline (−) and treated with 50 μM etoposide (ETOP) (+) or without ETOP (−) for 6 h. β-Actin was used as a loading control. (B) Flow cytometric analysis of p53 and HCV core protein expression in UHCV-11 cells treated as described for panel A. (C) Flow cytometric analysis of p21 and HCV core protein expression in UHCV-11 cells treated as described for panel A. Quadrants are based on staining with isotype control antibodies. The frequency of events in each quadrant is represented as the percentage of total gated events.CC BY · PubMed Central
FIG 5 p21 and p53 transcript levels during HCV infection. (A) RNA flow cytometric analysis of HCV RNA-electroporated HepG2/miR-122 cells. Cells were gated into uninfected (-) versus infected (+) populations based on detection of HCV RNA. (B) p21 mRNA levels in cells without HCV RNA [HCV RNA (-)] versus cells with HCV RNA [HCV RNA (+)]. The cells were treated with 50 μM ETOP or DMSO control for 6 h. (C) p53 mRNA levels in HCV RNA (-) cells versus HCV RNA (+) cells treated as described for panel B.
FIG 5 p21 and p53 transcript levels during HCV infection. (A) RNA flow cytometric analysis of HCV RNA-electroporated HepG2/miR-122 cells. Cells were gated into uninfected (-) versus infected (+) populations based on detection of HCV RNA. (B) p21 mRNA levels in cells without HCV RNA [HCV RNA (-)] versus cells with HCV RNA [HCV RNA (+)]. The cells were treated with 50 μM ETOP or DMSO control for 6 h. (C) p53 mRNA levels in HCV RNA (-) cells versus HCV RNA (+) cells treated as described for panel B.CC BY · PubMed Central
FIG 6 HCV inhibition of p53 activation is independent of MDM2 and proteasome activity. (A) p53 accumulation in HCV core (-) versus HCV core (+) populations of HepG2/miR-122 cells electroporated with indicated HCV RNA genomes and after 72 h, treated with 10 μM MDM2 inhibitor (nutlin-3) or DMSO for an additional 6 h. The numbers indicate the percentages of p53-positive cells following nutlin-3 treatment. (B) p53 accumulation in HCV core (-) versus HCV core (+) populations treated with 250 nM proteasome inhibitor (epoxomycin [EPX]) or DMSO for 6 h. The numbers indicate the percentages of p53-positive cells following EPX treatment.
FIG 6 HCV inhibition of p53 activation is independent of MDM2 and proteasome activity. (A) p53 accumulation in HCV core (-) versus HCV core (+) populations of HepG2/miR-122 cells electroporated with indicated HCV RNA genomes and after 72 h, treated with 10 μM MDM2 inhibitor (nutlin-3) or DMSO for an additional 6 h. The numbers indicate the percentages of p53-positive cells following nutlin-3 treatment. (B) p53 accumulation in HCV core (-) versus HCV core (+) populations treated with 250 nM proteasome inhibitor (epoxomycin [EPX]) or DMSO for 6 h. The numbers indicate the percentages of p53-positive cells following EPX treatment.CC BY · PubMed Central
FIG 7 PKR is activated in HCV-infected cultured cells and during acute HCV infection in vivo. (A) Immunoblots of total PKR, active PKR (pT446), and HCV core protein in control and PKR knockout (PKRKO) HepG2/miR-122 cells 72 h after electroporation with the indicated HCV RNA. β-Actin was used as a loading control. (B) Flow cytometric analysis of activated PKR (pT446) in HCV core (-) and HCV core (+) populations of control HepG2/miR-122 cells. (C) Detection of phospho-PKR (T446) in chimpanzee liver by immunohistochemistry (IHC). Representative images of liver sections stained for phospho-PKR are shown for animal 4X0395 at 6 weeks prechallenge (wk -6) or at 6 or 11 weeks postchallenge with HCV. The far right panel shows a liver section from animal 4X0395 at week 11 that was stained according to the same protocol but with the omission of the primary antibody (Ab). Bars = 100 µm. (D) Diagram showing workflow of image analysis and phospho-PKR (p-PKR) quantitation in IHC images. Hepatocytes were identified based on size and nuclear hematoxylin stain. Hemosiderin deposits were evident in some samples, and these regions were excluded from analyses. The magenta chromogen (phospho-PKR) was quantified on a per cell basis and categorized as absent/low, medium, or high based on the observed range. (E) Quantitation of phospho-PKR in liver sections from three chimpanzees pre- and postchallenge with HCV. For each time point, viral loads in serum and liver (expressed as genome equivalents [GE]) and serum alanine aminotransferase (ALT) levels are shown.
FIG 7 PKR is activated in HCV-infected cultured cells and during acute HCV infection in vivo. (A) Immunoblots of total PKR, active PKR (pT446), and HCV core protein in control and PKR knockout (PKRKO) HepG2/miR-122 cells 72 h after electroporation with the indicated HCV RNA. β-Actin was used as a loading control. (B) Flow cytometric analysis of activated PKR (pT446) in HCV core (-) and HCV core (+) populations of control HepG2/miR-122 cells. (C) Detection of phospho-PKR (T446) in chimpanzee liver by immunohistochemistry (IHC). Representative images of liver sections stained for phospho-PKR are shown for animal 4X0395 at 6 weeks prechallenge (wk -6) or at 6 or 11 weeks postchallenge with HCV. The far right panel shows a liver section from animal 4X0395 at week 11 that was stained according to the same protocol but with the omission of the primary antibody (Ab). Bars = 100 µm. (D) Diagram showing workflow of image analysis and phospho-PKR (p-PKR) quantitation in IHC images. Hepatocytes were identified based on size and nuclear hematoxylin stain. Hemosiderin deposits were evident in some samples, and these regions were excluded from analyses. The magenta chromogen (phospho-PKR) was quantified on a per cell basis and categorized as absent/low, medium, or high based on the observed range. (E) Quantitation of phospho-PKR in liver sections from three chimpanzees pre- and postchallenge with HCV. For each time point, viral loads in serum and liver (expressed as genome equivalents [GE]) and serum alanine aminotransferase (ALT) levels are shown.CC BY · PubMed Central
FIG 8 PKR is required for HCV-mediated inhibition of p53. (A) Levels of phosphorylated eIF2α (pS51) (left) and global protein synthesis (right) in HCV core (-) and HCV core (+) populations of control versus PKRKO cells. (B) MFI values for global protein synthesis from the indicated populations of control and PKRKO cell lines are expressed as the percentages of protein synthesis relative to JFH1/GND-electroporated controls. (C) Control cells were labeled in the presence or absence of the translational inhibitor cycloheximide (CHX) (50 μg/ml) to confirm specificity for newly synthesized proteins. Values in panels B and C represent the means ± SEM from three independent experiments. ***, P < 0.0001 by two-way ANOVA with Bonferroni’s correction for multiple comparisons. (D) p53 accumulation in HCV core (-) and HCV core (+) populations of control versus PKRKO cells electroporated with the indicated HCV RNA and treated 72 h later with 100 μM etoposide (ETOP) or DMSO for 2 h. Numbers indicate the percentages of p53-positive cells following etoposide treatment. (E) Immunofluorescence confocal microscopy for p53 and HCV core protein in JFH1-QL RNA-electroporated PKRKO cells treated as described for panel D. Nuclei were labeled with DAPI. Bar, 50 μm.
FIG 8 PKR is required for HCV-mediated inhibition of p53. (A) Levels of phosphorylated eIF2α (pS51) (left) and global protein synthesis (right) in HCV core (-) and HCV core (+) populations of control versus PKRKO cells. (B) MFI values for global protein synthesis from the indicated populations of control and PKRKO cell lines are expressed as the percentages of protein synthesis relative to JFH1/GND-electroporated controls. (C) Control cells were labeled in the presence or absence of the translational inhibitor cycloheximide (CHX) (50 μg/ml) to confirm specificity for newly synthesized proteins. Values in panels B and C represent the means ± SEM from three independent experiments. ***, P < 0.0001 by two-way ANOVA with Bonferroni’s correction for multiple comparisons. (D) p53 accumulation in HCV core (-) and HCV core (+) populations of control versus PKRKO cells electroporated with the indicated HCV RNA and treated 72 h later with 100 μM etoposide (ETOP) or DMSO for 2 h. Numbers indicate the percentages of p53-positive cells following etoposide treatment. (E) Immunofluorescence confocal microscopy for p53 and HCV core protein in JFH1-QL RNA-electroporated PKRKO cells treated as described for panel D. Nuclei were labeled with DAPI. Bar, 50 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. National Institutes of Health . 2002. Public Health Service policy on humane care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD.
  2. US Department of Agriculture . 2013. Animal Welfare Act and animal welfare regulations. Animal and Plant Health Inspection Service, US Department of Agriculture, Washington, DC.

Cited by

See all 40

Metadata

Authors
Mitchell, J. K., Midkiff, B. R., Israelow, B., Evans, M. J., Lanford, R. E., Walker, C. M., Lemon, S. M., & McGivern, D. R.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Texas Biomedical Research Institute (US)
  • Nationwide Children's Hospital (US)
Corresponding author
  • Lemon, Stanley M.
  • McGivern, David R.
Venue
mBio
Published
2017-05-03
Volume
8
Issue
2
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2609960515
Cited by
38
References
52
Citations by year
2026: 3 · 2025: 8 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 2
FWCI
2.20
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UNC Libraries
Funders
  • HHS | NIH | National Cancer Institute (T32-CA009156, F32-CA192633, R01-CA164029, P30-CA016086)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (T32-AI07647, R01-AI095690, R37-AI047367, R21-AI115207)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F30-DK096892, R01-DK095125)
  • HHS | NIH | NIH Office of the Director (P51-OD011133)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
hepatitis C virus, p53, PKR, DNA damage response, HCV replication, hepatocellular carcinoma, miR-122, etoposide, Nutlin-3, CRISPR/Cas9, double-stranded RNA, host-virus interaction, viral oncogenesis, chimpanzees
MeSH terms
Animals, Pan troglodytes, Disease Models, Animal, Hepatitis C, Humans, Tumor Suppressor Protein p53, Hepacivirus, eIF-2 Kinase, Host-Pathogen Interactions, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.